Keep pulling the thread on Andrew Dudum.
Hims & Hers deploys approximately $1 billion in marketing spend annually across its brands.
Hims & Hers has reduced the price of its GLP-1 weight loss drug offering to $149, down from an initial self-pay price of $300-$400 eighteen months ago.
The cash-pay price for blockbuster GLP-1 drugs has been cut by approximately 80%, from thousands of dollars to between $150 and $200.
Andrew Dudum asserts that the US pharmaceutical distribution model has fundamentally changed in the last 18 months, shifting away from PBMs and insurance towards direct-to-consumer platforms.
Hims & Hers acquired Australian digital health company Eucalyptus for approximately $1.5 billion in cash.
Hims & Hers is spending hundreds of millions of dollars to vertically integrate its diagnostics capabilities, including owning the collection devices and lab processing facilities.
The long-term vision for Hims & Hers is to offer a comprehensive 50-biomarker blood panel for free as part of its membership, serving as a preventative front door to its services.
In the last six months, the stock for Hims & Hers has declined by 66%.
As of the recording date, Hims & Hers has a market capitalization of $4.35 billion.
Hims & Hers generates over $2.3 billion in annual revenue.
Hims & Hers went public approximately 36 months after its initial launch.
Andrew Dudum's hiring strategy at Hims & Hers prioritizes candidates with grit who have experience as builders and have overcome significant challenges, rather than those with credentials from prestigious tech companies.